Abstract Introduction As the incidence of metastatic spine disease (MSD) increases, treatments to manage refractory pain, pathologic vertebral body fractures, and spinal cord compression are becoming increasingly common. Given the palliative nature of surgical intervention used to achieve tumor control and thus mitigat...
Andrew A. Hardigan, G. B. Brodano, Christina Griffoni et al.· Neuro-Oncology Advances· 0 citations
Abstract Introduction Given the palliative nature of treatment for metastatic spine disease (MSD), measuring surgical outcomes in this population requires examining comprehensive outcome variables. We sought to achieve an international consensus in how to measure success in the MSD population. Methods The AO Spine Know...
Andrew A. Hardigan, R. de la Garza Ramos, Michael H. Weber et al.· Neuro-Oncology Advances· 0 citations
Frailty and sarcopenia are common in the MSD population and multidimensional measurements of health that must be carefully considered with regard to treatment decision making, however, this review reinforces the lack of readily available tool to quantify both conditions and their effect on outcomes.
Eli Johnson, Mark A. Maclean, Antoinette J. Charles et al.· Neuro-Oncology Advances· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
